RTI Biologics, Inc. (RTIX)

[surf1944]

8:06AM RTI Biologics reports EPS in-line, misses on revs; guides Q1 EPS below consensus, revs below consensus; guides FY13 EPS below consensus, revs below consensus (RTIX) 4.74 : Reports Q4 (Dec) earnings of $0.04 per share, in-line with the Capital IQ Consensus Estimate consensus of $0.04; revenues rose 4.0% year/year to $44.6 mln vs the $45.11 mln consensus.

Co issues downside guidance for Q1, sees EPS of ~$0.02 vs. $0.05 Capital IQ Consensus Estimate; sees Q1 revs of $38-39 mln vs. $46.04 mln Capital IQ Consensus Estimate. Co issues downside guidance for FY13, sees EPS of $0.17-0.19 vs. $0.22 Capital IQ Consensus Estimate; sees FY13 revs of $178-182 mln vs. $188.49 mln Capital IQ Consensus Estimate.

"Due to customer reaction to the FDA warning letter and inaccuracies in media coverage in 2012, we expect a weaker first half of the year. Following the anticipated closure of the warning letter, expansion of our direct distribution business and the launch of several new implants, we expect the second half of the year to be strong," said Hutchison. "We also expect that the investments we are making in new products and direct distribution, combined with our active business development efforts, will accelerate our future revenue growth.